People
Biotech and pharma companies strengthen their executive leadership and board positions.
Immigration has been a central concern of President Donald Trump. Since taking office, his administration has put forth a number of policies to restrict the number of immigrants allowed each year, as well as from what nations those immigrants can come.
A month after beleaguered Merrimack Pharmaceuticals announced it was terminating its staff and leadership team, the company’s chief executive officer and chief financial officer have resigned their positions. But, they are both remaining with the company as high-paid consultants.
The explosion, which is still being investigated, happened at Xumei Biotech Co. Ltd. in Weishi County, part of China’s Henan Province.
Financial details of the deal were not disclosed, but Lonza said it plans to retain the Novartis employees currently working at the facility.
Two months after taking over as interim chief executive officer of Bay Area-based uBiome, John Rakow is stepping down from the company that has been under scrutiny from the Federal Bureau of Investigation (FBI).
Gottlieb’s knowledge of the regulatory and political landscape will be a boon for Pfizer as it dives deeper into oncology.
The Society for Clinical Research Sites announced that Jennifer Burgess, executive director of communications and engagement for TransCelerate BioPharma Inc. has joined the organization’s Leadership Council.
STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, announced the appointment of Dr John Haurum as an independent Non-Executive Director with immediate effect.
Polyphor AG announced the appointment of Frank Weber, M.D., as Chief Medical and Development Officer, effective September 1, 2019.
PRESS RELEASES